drugset / Trial / NCT00702806

Investigate Dose of Org 36286 to Initiate Multiple Follicular Growth in a Controlled Ovarian Hyperstimulation Protocol for IVF or IVF/ICSI (P07015)

NCT00702806

Phase 2 Completed 99 enrolled Organon and Co
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of this trial was to investigate the appropriate dose of a single injection of Org 36286 to initiate multifollicular growth for the first seven days in a controlled ovarian hyperstimulation (COH) protocol for IVF and IVF/ICSI. After seven days, participants were converted to treatment with Puregon® 150 IU and administration of the GnRH antagonist Orgalutran® to finalize the stimulation cycle. Secondary objectives were the safety (including the absence of antibody formation) and the direct effects of Org 36286 on reproductive functions (steroidogenesis, oocyte maturation, embryo quality and implantation).

Timeline

Start
2001-07-01
Primary completion
2002-10-15
Completion
2002-10-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Corifollitropin alfa Protein / enzyme biologic 120 ug Other
Subject Corifollitropin alfa Protein / enzyme biologic 180 ug Other
Subject Corifollitropin alfa Protein / enzyme biologic 240 ug Other
Subject Follitropin beta Protein / enzyme biologic 150 iu Subcutaneous
Background Ganirelix Protein / enzyme biologic 0.25 mg Subcutaneous
Background human chorionic gonadotropin Protein / enzyme biologic 10000 iu Subcutaneous

Indications